TY - JOUR
T1 - Safety and efficacy of the surpass streamline for intracranial aneurysms (SESSIA)
T2 - A multi-center US experience pooled analysis
AU - Vivanco-Suarez, Juan
AU - Mendez-Ruiz, Alan
AU - Farooqui, Mudassir
AU - Bekelis, Kimon
AU - Singer, Justin A.
AU - Javed, Kainaat
AU - Altschul, David J.
AU - Fifi, Johanna T.
AU - Matsoukas, Stavros
AU - Cooper, Jared
AU - Al-Mufti, Fawaz
AU - Gross, Bradley
AU - Jankowitz, Brian
AU - Kan, Peter T.
AU - Hafeez, Muhammad
AU - Orru, Emanuele
AU - Dajles, Andres
AU - Galecio-Castillo, Milagros
AU - Zevallos, Cynthia B.
AU - Wakhloo, Ajay K.
AU - Ortega-Gutierrez, Santiago
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Stryker Neurovascular, (grant number 2020-HEM-006).
Funding Information:
Santiago Ortega-Gutierrez is a consultant for Medtronic and Stryker Neurovascular: modest Justin A. Singer is consultant, proctor, spears bureau, grant support, and site PI (Evolve Trial) for Stryker Neurovascular; consultant and speakers bureau for Medtronic; part of the clinical events committee for Cerenovus. Fawaz Al-Mufti is consultant for Stryker, Penumbra and Cerenovus . Peter T. Kan is consultant for Stryker Neurovascular. Ajay K. Wakhloo is a consultant for Stryker Neurovascular: significant; Cerenovus JNJ: modest; receives research support from Philips Medical and a fellowship grant from Medtronic, co-founder and major stockholder in InNeuroCo, Deinde, and Neurofine. Stocks in ThrombX, RIST, NovaSignal. Analytics 4Life, Microbot. Johanna T Fifi is consultant for Stryker Neurovascular.
Publisher Copyright:
© The Author(s) 2022.
PY - 2022
Y1 - 2022
N2 - Background and purpose: Flow diversion has established as standard treatment for intracranial aneurysms, the Surpass Streamline is the only FDA-approved braided cobalt/chromium alloy implant with 72-96 wires. We aimed to determine the safety and efficacy of the Surpass in a post-marketing large United States cohort. Materials and methods: This is a retrospective multicenter study of consecutive patients treated with the Surpass for intracranial aneurysms between 2018 and 2021. Baseline demographics, comorbidities, and aneurysm characteristics were collected. Efficacy endpoint included aneurysm occlusion on radiographic follow-up. Safety endpoints were major ipsilateral ischemic stroke or treatment-related death. Results: A total of 277 patients with 314 aneurysms were included. Median age was 60 years, 202 (73%) patients were females. Hypertension was the most common comorbidity in 156 (56%) patients. The most common location of the aneurysms was the anterior circulation in 89% (279/314). Mean aneurysm dome width was 5.77 ± 4.75 mm, neck width was 4.22 ± 3.83 mm, and dome/neck ratio was 1.63 ± 1.26. Small-sized aneurysms were 185 (59%). Single device was used in 94% of the patients, mean number of devices per patient was 1.06. At final follow-up, complete obliteration rate was 81% (194/239). Major stroke and death were encountered in 7 (3%) and 6 (2%) cases, respectively. Conclusion: This is the largest cohort study using a 72–96 wire flow diverter. The Surpass Streamline demonstrated a favorable safety and efficacy profile, making it a valuable option for treating not only large but also wide-necked small and medium-sized intracranial aneurysms.
AB - Background and purpose: Flow diversion has established as standard treatment for intracranial aneurysms, the Surpass Streamline is the only FDA-approved braided cobalt/chromium alloy implant with 72-96 wires. We aimed to determine the safety and efficacy of the Surpass in a post-marketing large United States cohort. Materials and methods: This is a retrospective multicenter study of consecutive patients treated with the Surpass for intracranial aneurysms between 2018 and 2021. Baseline demographics, comorbidities, and aneurysm characteristics were collected. Efficacy endpoint included aneurysm occlusion on radiographic follow-up. Safety endpoints were major ipsilateral ischemic stroke or treatment-related death. Results: A total of 277 patients with 314 aneurysms were included. Median age was 60 years, 202 (73%) patients were females. Hypertension was the most common comorbidity in 156 (56%) patients. The most common location of the aneurysms was the anterior circulation in 89% (279/314). Mean aneurysm dome width was 5.77 ± 4.75 mm, neck width was 4.22 ± 3.83 mm, and dome/neck ratio was 1.63 ± 1.26. Small-sized aneurysms were 185 (59%). Single device was used in 94% of the patients, mean number of devices per patient was 1.06. At final follow-up, complete obliteration rate was 81% (194/239). Major stroke and death were encountered in 7 (3%) and 6 (2%) cases, respectively. Conclusion: This is the largest cohort study using a 72–96 wire flow diverter. The Surpass Streamline demonstrated a favorable safety and efficacy profile, making it a valuable option for treating not only large but also wide-necked small and medium-sized intracranial aneurysms.
KW - flow diverter
KW - interventional
KW - Intracranial aneurysm
KW - subarachnoid hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=85135736405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135736405&partnerID=8YFLogxK
U2 - 10.1177/15910199221118148
DO - 10.1177/15910199221118148
M3 - Article
C2 - 35934939
AN - SCOPUS:85135736405
SN - 1591-0199
JO - Interventional Neuroradiology
JF - Interventional Neuroradiology
ER -